Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

I’d recommend checking out my last article, where I took a deeper look at some of Novo Nordisk’s most promising pipeline treatments for diabetes, like IcoSema or oral semaglutide. Obesity ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

New York, New York--(Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk ... 2.4 mg semaglutide ...

semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweigh Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk ... and 2.4 mg semaglutide for ...

But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens. So compounded semaglutide is sold in a vial with a separate syringe. Compounding drugs isn’t ...

GLP-1 agonist semaglutide is the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around $8 billion last year. Supply constraints have meant that ...

Although the ad does not identify the medication, Hims & Hers offers compounded versions of the weight-loss drug semaglutide, which was developed by Novo Nordisk and is typically sold under the ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...